Unlocking the potential of immuno-oncology in advanced basal cell carcinoma - European Medical Journal

Unlocking the potential of immuno-oncology in advanced basal cell carcinoma



This symposium covers unmet needs in the treatment approach and management of advanced BCC. There is no standard of care post hedgehog inhibitor therapy in advanced BCC. The first part of this symposium discusses the results from an expert consensus panel which included a new treatment approach using immunotherapy. This is followed by a discussion around the clinical data results available using immunotherapy in advanced BCC post hedgehog inhibitor therapy. The symposium ends with a discussion of real world clinical cases to inform treatment approach in advanced BCC.

Professor Salvador Martín-Algarra — Current treatment landscape in advanced BCC

Professor Dirk Schadendorf — Treatment paradigm and emerging approaches in advanced BCC

Professor Christoph Hoeller — Clinical implications of immunotherapy for advanced BCC


The views expressed in the following presentations are those of the individual authors and do not necessarily reflect the views of Sanofi Genzyme and Regeneron. Sanofi Genzyme and Regeneron do not recommend the use of their products in any manner inconsistent with that described in the full prescribing information available in your country. Before prescribing the product, always refer to the prescribing information and medical guidance in your country. The information shared during this conference is provided for medical and scientific purposes only.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now